<DOC>
	<DOCNO>NCT00138658</DOCNO>
	<brief_summary>This clinical study help determine give OGX-011 ( custirsen sodium ) combination gemcitabine ( GEM ) cisplatin ( CIS ) carboplatin ( CARB ) safe effective treatment patient lung cancer . This study help assess safety anti-tumor effect OGX-011 give patient combination GEM CIS/CARB .</brief_summary>
	<brief_title>A Study OGX-011/Gemcitabine/Platinum-Based Regimen Stage IIIB/IV Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>OGX-011 experimental drug show increase effectiveness commonly use cancer therapy chemotherapy , radiation hormone therapy several kind cancer type animal . OGX-011 study treatment cancer patient combination chemotherapy . In human , OGX-011 combination hormone therapy show decrease tissue level protein call clusterin , overproduce cancer cell . Clusterin find block cell death make cell resistant cancer therapy . Gemcitabine ( GEM ) , cisplatin ( CIS ) carboplatin ( CARB ) approve Health Canada Food Drug Administration United States treatment patient lung cancer . OGX-011 administered 2-hr intravenous ( IV ) infusion Days -7 , -5 , -3 prior Cycle 1 , weekly Days 1 , 8 , 15 21-day cycle ; GEM infuse IV OGX-011 Days 1 8 ; either CIS CARB infuse IV GEM Day 1 cycle . Six cycle treatment plan . Most patient receive OGX-011 640 mg , 3 patient receive OGX-011 480 mg dose ; OGX-011 dose group combine due small number patient receive 480 mg .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients must histologically cytologically confirm diagnosis NSCLC must chemotherapy biological therapy disease . 2 . Stage IIIB ( N3 and/or pleural pericardial effusion ) IV disease amenable either surgery radiation therapy curative intent . 3 . Life expectancy ≥ 12 week 4 . If patient prior radiation therapy : lesion ( ) use determination response previously irradiate increase size since completion radiotherapy ; patient recover toxicity radiotherapy . 5 . Radiotherapy lesion ( ) use determination response complete least 6 week prior treatment ; radiotherapy site complete least 2 week prior treatment . 6 . At least one unidimensionally measurable lesion meeting Response Evaluation Criteria Solid Tumors [ RECIST ] ( least 10 mm long diameter spiral compute tomography [ CT ] scan , least 20 mm standard technique ) . 7 . ECOG status must ≤ 1 Exclusion Criteria 1 . Prior chemotherapy biological therapy ( approved experimental ) NSCLC , include adjuvant neoadjuvant treatment . 2 . Presence central nervous system ( CNS ) metastases , unless patient complete successful local therapy CNS metastasis , exception leptomeningeal disease patient exclude . Patients must corticosteroids least 21 day prior start treatment . 3 . Second primary malignancy ( except situ carcinoma cervix , adequately treat nonmelanomatous skin cancer , clinically localized prostate cancer , superficial bladder cancer malignancy treat least 3 year previously evidence recurrence ) . 4 . Patients eligible combined modality therapy curative intent define combination chemotherapy , radiation therapy and/or surgery . ( This criterion intend exclude patient stage IIIB disease , define presence N3 nodal status , report cure rate high 10 % treat combined modality therapy . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>custirsen sodium</keyword>
	<keyword>OGX-011</keyword>
	<keyword>Stage IIIB IV advance non-small cell lung cancer</keyword>
</DOC>